Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer
Cancer research continues to advance the outcome of patients with cancer as reflected by the higher survival rates and better quality of life. In an effort to enhance outcomes, researchers are focused on evaluating therapies with more effectiveness as well as lesser toxicities. Despite recent discoveries and advances in medicine, pancreatic cancer (PC) has a very poor prognosis that urgently requires novel therapeutic approaches. Currently, the five-year survival rate for PC is 8% (Siegel et al., 2017).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Myrna Hurtado, Umesh T. Sankpal, Amalendu Ranjan, Rajasekhar Maram, Jamboor K. Vishwanatha, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Riyaz Basha Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Pancreas | Pancreatic Cancer | Toxicology